Phase I and Clinical Pharmacology Citations 1-25 of 177 total displayed. Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy Charles J. Ryan, Matthew R. Smith, Lawrence Fong, Jonathan E. Rosenberg, Philip Kantoff, Florence Raynaud, Vanessa Martins, Gloria Lee, Thian Kheoh, Jennifer Kim, Arturo Molina, Eric J. Small JCO Mar 2010: 1481-1488. Abstract Full Text PDF CiteTrack Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors Ramesh K. Ramanathan, Merrill J. Egorin, Charles Erlichman, Scot C. Remick, Suresh S. Ramalingam, Cynthia Naret, Julianne L. Holleran, Cynthia J. TenEyck, S. Percy Ivy, Chandra P. Belani JCO Mar 2010: 1520-1526. Abstract Full Text PDF CiteTrack Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer Jean-Charles Soria, Egbert Smit, David Khayat, Benjamin Besse, Xinqun Yang, Cheng-Pang Hsu, David Reese, Jeffrey Wiezorek, Fiona Blackhall JCO Mar 2010: 1527-1533. Abstract Full Text PDF CiteTrack Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma Kazuhito Yamamoto, Atae Utsunomiya, Kensei Tobinai, Kunihiro Tsukasaki, Naokuni Uike, Kimiharu Uozumi, Kazunari Yamaguchi, Yasuaki Yamada, Shuichi Hanada, Kazuo Tamura, Shigeo Nakamura, Hiroshi Inagaki, Koichi Ohshima, Hitoshi Kiyoi, Takashi Ishida, Kouji Matsushima, Shiro Akinaga, Michinori Ogura, Masao Tomonaga, Ryuzo Ueda JCO Mar 2010: 1591-1598. Abstract Full Text PDF CiteTrack Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials Christophe Le Tourneau, Anastasios Stathis, Laura Vidal, Malcolm J. Moore, Lillian L. Siu JCO Mar 2010: 1401-1407. Abstract Full Text PDF CiteTrack Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study Josep Tabernero, Andres Cervantes, Fernando Rivera, Erika Martinelli, Federico Rojo, Anja von Heydebreck, Teresa Macarulla, Edith Rodriguez-Braun, Maria Eugenia Vega-Villegas, Stefanie Senger, Francisco Javier Ramos, Susana Roselló, Ilhan Celik, Christopher Stroh, José Baselga, Fortunato Ciardiello JCO Mar 2010: 1181-1189. Abstract Full Text PDF Data Supplement CiteTrack NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia Jeffrey E. Rubnitz, Hiroto Inaba, Raul C. Ribeiro, Stanley Pounds, Barbara Rooney, Teresa Bell, Ching-Hon Pui, Wing Leung JCO Feb 2010: 955-959. Abstract Full Text PDF CiteTrack Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens, Lia Gore, D. Ross Camidge, Sami Diab, Stephen Leong, Cindy O'Bryant, Laura Q.M. Chow, Natalie J. Serkova, Neal J. Meropol, Nancy L. Lewis, E. Gabriela Chiorean, Floyd Fox, Hagop Youssoufian, Eric K. Rowinsky, S. Gail Eckhardt JCO Feb 2010: 780-787. Abstract Full Text PDF CiteTrack Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors A. Craig Lockhart, Mace L. Rothenberg, Jakob Dupont, Wendy Cooper, Paul Chevalier, Lars Sternas, Giliane Buzenet, Elizabeth Koehler, Jeffrey A. Sosman, Lawrence H. Schwartz, David H. Gultekin, Jason A. Koutcher, Edwin F. Donnelly, Ric Andal, Isabelle Dancy, David R. Spriggs, William P. Tew JCO Jan 2010: 207-214. Abstract Full Text PDF CiteTrack Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Robert Westwood, Simon R. Green, Judy H. Chiao, Patricia A. Boone, Jorge Cortes, William Plunkett JCO Jan 2010: 285-291. Abstract Full Text PDF CiteTrack Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial Apostolia-Maria Tsimberidou, Fadi Braiteh, David J. Stewart, Razelle Kurzrock JCO Dec 2009: 6243-6250. Abstract Full Text PDF CiteTrack Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1 Anthony W. Tolcher, John Sarantopoulos, Amita Patnaik, Kyriakos Papadopoulos, Chia-Chi Lin, Jordi Rodon, Barbara Murphy, Bruce Roth, Ian McCaffery, Kevin S. Gorski, Brianne Kaiser, Min Zhu, Hongjie Deng, Greg Friberg, Igor Puzanov JCO Dec 2009: 5800-5807. Abstract Full Text PDF CiteTrack Histone Deacetylase Inhibitors in Cancer Therapy Andrew A. Lane, Bruce A. Chabner JCO Nov 2009: 5459-5468. Abstract Full Text PDF CiteTrack Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers Nancy L. Lewis, Lionel D. Lewis, Joseph P. Eder, Nandi J. Reddy, Feng Guo, Kristen J. Pierce, Anthony J. Olszanski, Roger B. Cohen JCO Nov 2009: 5262-5269. Abstract Full Text PDF Data Supplement CiteTrack Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett, Sharad V. Rawale, Daniele Vicari, Jennifer M. Thurmond, Tammy Lamb, Aruna Mani, Yahaira Kane, Catherine R. Balint, Donald Chalupa, Gregory A. Otterson, Charles L. Shapiro, Jeffrey M. Fowler, Michael R. Grever, Tanios S. Bekaii-Saab, William E. Carson, III JCO Nov 2009: 5270-5277. Abstract Full Text PDF CiteTrack Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom, Jaap Verweij, Johan W.R. Nortier, Jan Ouwerkerk, Conny van Noort, Mariangela Mariani, Riccardo Spinelli, Patrizia Carpinelli, Bernard Laffranchi, Maja J.A. de Jonge JCO Oct 2009: 5094-5101. Abstract Full Text PDF CiteTrack Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium Tanya M. Trippett, Cynthia Herzog, James A. Whitlock, Johannes Wolff, John Kuttesch, Rochelle Bagatell, Stephen P. Hunger, Jessica Boklan, Amy A. Smith, Robert J. Arceci, Howard M. Katzenstein, Christopher Harbison, Xiaofei Zhou, Haolan Lu, Christiane Langer, Martin Weber, Lia Gore JCO Oct 2009: 5102-5108. Abstract Full Text PDF CiteTrack Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies Chiung-Ing Wong, Tong-San Koh, Ross Soo, Septian Hartono, Choon-Hua Thng, Evelyn McKeegan, Wei-Peng Yong, Chien-Shing Chen, Soo-Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse, Boon-Cher Goh JCO Oct 2009: 4718-4726. Abstract Full Text PDF CiteTrack Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia Aaron D. Schimmer, Elihu H. Estey, Gautam Borthakur, Bing Z. Carter, Gary J. Schiller, Martin S. Tallman, Jessica K. Altman, Judith E. Karp, Jeannine Kassis, David W. Hedley, Joseph Brandwein, Wei Xu, Duncan H. Mak, Eric LaCasse, Christine Jacob, Stephen J. Morris, Jacques Jolivet, Michael Andreeff JCO Oct 2009: 4741-4746. Abstract Full Text PDF CiteTrack Phase I Drug Combination Trial Design: Walking the Tightrope Paul Hamberg, Jaap Verweij JCO Sep 2009: 4441-4443. Full Text PDF CiteTrack Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma Ranjana Advani, Andres Forero-Torres, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Hong Ren, Kate Harrop, Nancy Whiting, Jonathan G. Drachman JCO Sep 2009: 4371-4377. Abstract Full Text PDF CiteTrack Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity Nielka P. van Erp, Karel Eechoute, Astrid A. van der Veldt, John B. Haanen, An K.L. Reyners, Ron H.J. Mathijssen, Epie Boven, Tahar van der Straaten, Renée F. Baak-Pablo, Judith A.M. Wessels, Henk-Jan Guchelaar, Hans Gelderblom JCO Sep 2009: 4406-4412. Abstract Full Text PDF CiteTrack Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, Corey J. Langer, D. Ross Camidge, Kristin Padavic, Lia Gore, Margaret Smith, Laura Q. Chow, Margaret von Mehren, Cindy O'Bryant, Sujatha Hariharan, Sami Diab, Norma Lynn Fox, Renée Miceli, S. Gail Eckhardt JCO Sep 2009: 4413-4421. Abstract Full Text PDF CiteTrack Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy Guy A. van Hazel, Nick Pavlakis, David Goldstein, Ian N. Olver, Michael J. Tapner, David Price, Geoffrey D. Bower, Gregory M. Briggs, Monica A. Rossleigh, D. James Taylor, Jacob George JCO Sep 2009: 4089-4095. Abstract Full Text PDF CiteTrack Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors Ferry A.L.M. Eskens, Neeltje Steeghs, Jaap Verweij, Johan L. Bloem, Olaf Christensen, Leni van Doorn, Jan Ouwerkerk, Maja J.A. de Jonge, Johan W.R. Nortier, Joern Kraetzschmar, Prabhu Rajagopalan, Hans Gelderblom JCO Sep 2009: 4169-4176. Abstract Full Text PDF CiteTrack [Next page] Pages: 1 2 3 4 5 6 7 8

Sign up for Collection Alerts Collected Resources Home Related collections: 25th Anniversary Commentaries Art of Oncology Biology of Neoplasia Biostatistics and Clinical Trial Methodology Bone Marrow Transplantation Breast Cancer Cancer-Related Complications Clinical Guidelines Diagnosis and Staging Endocrine System Cancer Epidemiology, Cancer Prevention, and Control Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Head and Neck Cancer Health Services Research Hematologic Malignancies JCO Translations Melanoma Neurooncology Non-Melanoma Skin Cancer Notes from the Editors Patient and Survivor Care Pediatric Oncology Phase I and Clinical Pharmacology Radiation Oncology Sarcomas Surgical Oncology Thoracic Oncology Translational Oncology Treatment-Related Complications Tumor Imaging Unknown Primary Site and Rare Cancers